Munich – Adrenomed AG, a biopharmaceutical company specialising in the integrity and barrier function of blood vessels, has completed a EUR 24 million Series D financing round co-led by Wellington Partners and HBM Healthcare Investments. The capital raised will be used to drive forward the clinical development programme for product candidate Adrecizumab.
A CMS team headed by Munich-based partner Stefan-Ulrich Müller advised lead investors Wellington Partners and HBM on legal aspects of the transaction. Both investors are long-standing clients and regularly rely on CMS for legal support.
Based in Munich and Zurich, Wellington Partners is a leading European venture capital firm focusing on investment in early and growth-stage life science companies. It manages funds totalling more than EUR 1 billion, of which around EUR 400 million is committed to the life sciences sector.
Headquartered in Zug (Switzerland), HBM Healthcare Investments AG specialises in investment in the healthcare sector. Its portfolio includes companies engaged in human medicine, biotechnology, medical technology and diagnostics as well as related areas. With assets under management of more than EUR 1 billion, HBM has an international shareholder base and is listed on SIX Swiss Exchange.
Adrenomed AG of Hennigsdorf, near Berlin, is a privately-financed biopharmaceutical company engaged in clinical development projects. Established in 2009, the firm is pursuing a novel therapeutic approach to ensure the integrity and barrier function of blood vessels.
Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert, Partner
Johannes Steinacher, Associate
Anton Hieber, Associate
Sabine Renz, Associate, all Corporate/Venture Capital
Martina Hidalgo, Partner
Dr Christoph Ceelen, Senior Associate, both Labor, Employment & Pensions
Stefan Lüft, Partner
Theresa Dörendahl, Senior Associate, both Intellectual Property
Peter Endres, Partner, Commercial
Dr Reemt Matthiesen, Partner
Johanna M. Hofmann, Associate, both TMC
Stefan Lehr, Partner, Competition & EU